168 related articles for article (PubMed ID: 20055660)
121. The emerging role of lenalidomide in the management of lymphoid malignancies.
Hernandez-Ilizaliturri FJ; Batoo SA
Ther Adv Hematol; 2011 Feb; 2(1):45-53. PubMed ID: 23556075
[TBL] [Abstract][Full Text] [Related]
122. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.
Badoux XC; Keating MJ; Wen S; Wierda WG; O'Brien SM; Faderl S; Sargent R; Burger JA; Ferrajoli A
J Clin Oncol; 2013 Feb; 31(5):584-91. PubMed ID: 23270003
[TBL] [Abstract][Full Text] [Related]
123. Lenalidomide alone and in combination for chronic lymphocytic leukemia.
Chen CI
Curr Hematol Malig Rep; 2013 Mar; 8(1):7-13. PubMed ID: 23254517
[TBL] [Abstract][Full Text] [Related]
124. Lenalidomide in the treatment of chronic lymphocytic leukemia.
Cortelezzi A; Sciumè M; Reda G
Adv Hematol; 2012; 2012():393864. PubMed ID: 22851972
[TBL] [Abstract][Full Text] [Related]
125. Targeted treatment for chronic lymphocytic leukemia.
Masood A; Sher T; Paulus A; Miller KC; Chitta KS; Chanan-Khan A
Onco Targets Ther; 2011; 4():169-83. PubMed ID: 22162923
[TBL] [Abstract][Full Text] [Related]
126. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.
Chanan-Khan AA; Chitta K; Ersing N; Paulus A; Masood A; Sher T; Swaika A; Wallace PK; Mashtare TL; Wilding G; Lee K; Czuczman MS; Borrello I; Bangia N
Br J Haematol; 2011 Nov; 155(4):457-67. PubMed ID: 22010965
[TBL] [Abstract][Full Text] [Related]
127. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia.
Lee BN; Gao H; Cohen EN; Badoux X; Wierda WG; Estrov Z; Faderl SH; Keating MJ; Ferrajoli A; Reuben JM
Cancer; 2011 Sep; 117(17):3999-4008. PubMed ID: 21858802
[TBL] [Abstract][Full Text] [Related]
128. Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach.
Zent CS; Kay NE
Leuk Lymphoma; 2011 Aug; 52(8):1425-34. PubMed ID: 21649549
[TBL] [Abstract][Full Text] [Related]
129. Initial testing of lenalidomide by the pediatric preclinical testing program.
Reynolds CP; Kang MH; Keir ST; Gorlick R; Kolb EA; Lock R; Maris JM; Carol H; Morton CL; Billups CA; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2011 Oct; 57(4):606-11. PubMed ID: 21360651
[TBL] [Abstract][Full Text] [Related]
130. Refractory chronic lymphocytic leukemia--new therapeutic strategies.
Schnaiter A; Stilgenbauer S
Oncotarget; 2010 Nov; 1(7):472-482. PubMed ID: 21317446
[TBL] [Abstract][Full Text] [Related]
131. Lenalidomide in the treatment of chronic lymphocytic leukemia.
Itchaki G; Brown JR
Expert Opin Investig Drugs; 2017 May; 26(5):633-650. PubMed ID: 28388253
[TBL] [Abstract][Full Text] [Related]
132. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.
Shindiapina P; Brown JR; Danilov AV
Br J Haematol; 2014 Oct; 167(2):149-61. PubMed ID: 25040077
[TBL] [Abstract][Full Text] [Related]
133. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics.
Sher T; Miller KC; Lawrence D; Whitworth A; Hernandez-Ilizaliturri F; Czuczman MS; Miller A; Lawrence W; Bilgrami SA; Sood R; Wood MT; Block AW; Lee K; Chanan-Khan AA
Leuk Lymphoma; 2010 Jan; 51(1):85-8. PubMed ID: 20055660
[TBL] [Abstract][Full Text] [Related]
134. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
135. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.
Bühler A; Wendtner CM; Kipps TJ; Rassenti L; Fraser GA; Michallet AS; Hillmen P; Dürig J; Gregory SA; Kalaycio M; Aurran-Schleinitz T; Trentin L; Gribben JG; Chanan-Khan A; Purse B; Zhang J; De Bedout S; Mei J; Hallek M; Stilgenbauer S
Blood Cancer J; 2016 Mar; 6(3):e404. PubMed ID: 26967821
[TBL] [Abstract][Full Text] [Related]
136. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
137.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
138.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
139.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
140.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
